Compare EOLS & XFLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EOLS | XFLT |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 284.3M | 255.1M |
| IPO Year | 2018 | N/A |
| Metric | EOLS | XFLT |
|---|---|---|
| Price | $4.02 | $16.75 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $15.50 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 497.1K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 14.17% |
| EPS Growth | ★ 1.23 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $297,176,000.00 | N/A |
| Revenue This Year | $13.27 | N/A |
| Revenue Next Year | $17.62 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 11.61 | N/A |
| 52 Week Low | $3.86 | $3.02 |
| 52 Week High | $12.28 | $17.21 |
| Indicator | EOLS | XFLT |
|---|---|---|
| Relative Strength Index (RSI) | 37.79 | 89.17 |
| Support Level | N/A | $4.93 |
| Resistance Level | $4.99 | N/A |
| Average True Range (ATR) | 0.23 | 0.35 |
| MACD | -0.07 | 0.94 |
| Stochastic Oscillator | 12.83 | 96.75 |
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
XAI Octagon Floating Rate & Alternative Income Trust is a diversified, closed-end management investment company which invests in a dynamically managed portfolio of floating-rate credit instruments and other structured credit investments within the private markets. The Trust's investment objective is to seek attractive total return with an emphasis on income generation across multiple stages of the credit cycle.